Oct 7, 2026 —
An optogenetic gene therapy has restored measurable, if partial, vision to people blinded by retinitis pigmentosa, in results published in the New England Journal of Medicine. The work comes from the PIONEER trial (NCT03326336), led by the University of Pittsburgh with international collaborators and supported by GenSight Biologics.
The therapy delivers a gene for ChrimsonR, a light-sensing protein, to surviving retinal ganglion cells through a single injection into the eye using an AAV vector. Patients then wear light-amplifying goggles that stimulate the treated cells. All ten participants had advanced disease and were legally blind at the start.
Seven of the ten showed improved light sensitivity, and six of those gains were large enough to count as clinically meaningful. Some patients could locate an object and reach for it while wearing the goggles, and EEG recordings confirmed that visual signals were reaching the visual cortex. The treatment was safe, with mostly mild or moderate eye-related side effects; it did not restore normal vision or the ability to read.
